[Combinations of chemotherapy or radiotherapy with checkpoint inhibitors].

Date publication

janvier 2018

Journal

Biologie aujourd'hui

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François

Tous les auteurs :
Ghiringhelli F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30973135

Résumé

Recent advances in cancer immunotherapy with the development of anti-PD1/PD-L1 antibodies are revolutionizing cancer care. Nevertheless, the efficacy of these treatments in monotherapy is limited to a subpopulation representing about 25-30% of patients in most indications. The development of new strategies is based on combinations between standard treatments (cytotoxic chemotherapy and radiotherapy) and immunotherapy in order to find synergistic combinations.

Référence

Biol Aujourdhui. 2018 ;212(3-4):77-79